The Role of TLR4 and RSV F Protein in Immunity to RSV

TLR4 和 RSV F 蛋白在 RSV 免疫中的作用

基本信息

  • 批准号:
    7173903
  • 负责人:
  • 金额:
    $ 49.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-01-01 至 2008-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The respiratory tract is a major portal for pathogens. The bronchoalveolar macrophage, positioned at the mucosal surface, recognizes "pathogen associated molecular patterns (PAMPs)" through structures called "pattern recognition receptors (PRRs)." A family of closely related mammalian PRRs, the "Toll-like receptors (TLRs)," are transmembrane signaling molecules that respond to diverse PAMPs. The lipopolysaccharide (LPS) of Gram negative bacteria stimulates macrophages through TLR4 to elicit a pattern of gene expression that is strongly proinflammatory, e.g., TNF-a, IL-1¿, IL-12, and IFN-? resulting in a "Th1-type" cytokine milieu. Respiratory syncytial virus (RSV) is the leading cause of pneumonia and bronchiolitis in infants and young children worldwide, and has recently been attributed to increased morbidity and mortality in the elderly and immunosuppressed. In a failed clinical trial, a formalin-inactivated RSV (FI-RSV) vaccine led to exacerbated RSV disease. Vaccine-enhanced RSV disease, demonstrated by histopathology and airway hyperreactivity, are faithfully recapitulated in the cotton rat (S. hispidus), and is associated with a Th2-type pattern of cytokine gene expression. Vaccination with FI-RSV and a TLR4 agonist mitigates enhanced disease. Recently, the RSV fusion (F) protein was shown to be a TLR4 agonist. In vitro, cotton rat macrophages respond to LPS and F protein to elicit the same spectrum of inflammatory genes, although the F protein is less potent. The overall hypothesis to be tested is that the interaction of F protein with TLR4 is essential for establishment of a Thl-type milieu and that formalin fixation of RSV destroys the capacity of F to interact with TLR4, resulting in a Th2-type response. This proposal details novel experimental approaches: (i) to evaluate the contribution and regulation of F protein signaling through TLR4 to the development of a Th1-type cytokine profile, (ii) to determine the role of TLR4 in the development of RSV-mediated disease in vivo, and (iii) to determine if polymorphic forms of TLR4 previously associated with airway hyporesponsiveness to LPS exhibit diminished sensitivity to F protein and if they are overrepresented in a population at high risk for RSV. It is expected that at the completion of this grant, we will have determined the molecular basis for primary and vaccine-enhanced RSV disease, and have identified strategies for the development of a human RSV vaccine.
描述(由申请人提供):呼吸道是病原体的主要入口。位于粘膜表面的支气管肺泡巨噬细胞通过称为“模式识别受体(PRR)”的结构识别“病原体相关分子模式(PAMP)”。Toll样受体(TLR)是一个与哺乳动物PRR密切相关的家族,是响应不同PAMP的跨膜信号分子。革兰氏阴性菌的脂多糖(LPS)通过TLR 4刺激巨噬细胞以引发强烈促炎的基因表达模式,例如,TNF-α、IL-1 β、IL-12和IFN-?导致“Th 1型”细胞因子环境。呼吸道合胞病毒(RSV)是全球婴幼儿肺炎和细支气管炎的主要原因,最近被认为是老年人和免疫抑制者发病率和死亡率增加的原因。在一次失败的临床试验中,福尔马林灭活的RSV(FI-RSV)疫苗导致RSV疾病恶化。通过组织病理学和气道高反应性证实的疫苗增强的RSV疾病在棉鼠中被忠实地再现(S. hispidus),并且与细胞因子基因表达的Th 2型模式相关。用FI-RSV和TLR 4激动剂接种减轻增强的疾病。最近,RSV融合(F)蛋白显示为TLR 4激动剂。在体外,棉鼠巨噬细胞对LPS和F蛋白的反应引起相同谱的炎性基因,尽管F蛋白的效力较低。待检验的总体假设是F蛋白与TLR 4的相互作用对于建立Th 1型环境是必需的,并且RSV的福尔马林固定破坏F与TLR 4相互作用的能力,导致Th 2型应答。该提案详细介绍了新的实验方法:(i)评估F蛋白信号通过TLR 4对Th 1型细胞因子谱的发展的贡献和调节,(ii)确定TLR 4在体内RSV介导的疾病的发展中的作用,以及(iii)确定以前与气道对LPS低反应性相关的TLR 4多态性是否表现出对F蛋白的敏感性降低,他们在RSV高危人群中比例过高。预计在该资助完成时,我们将确定原发性和疫苗增强型RSV疾病的分子基础,并确定开发人RSV疫苗的策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JORGE C BLANCO其他文献

JORGE C BLANCO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JORGE C BLANCO', 18)}}的其他基金

Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
  • 批准号:
    10591804
  • 财政年份:
    2023
  • 资助金额:
    $ 49.07万
  • 项目类别:
RSV-induced M2 macrophage differentiation: role of TLR4/PPARg/RXR signaling axis (80)
RSV 诱导的 M2 巨噬细胞分化:TLR4/PPARg/RXR 信号轴的作用 (80)
  • 批准号:
    10418803
  • 财政年份:
    2021
  • 资助金额:
    $ 49.07万
  • 项目类别:
RSV-induced M2 macrophage differentiation: role of TLR4/PPARg/RXR signaling axis (80)
RSV 诱导的 M2 巨噬细胞分化:TLR4/PPARg/RXR 信号轴的作用 (80)
  • 批准号:
    10287155
  • 财政年份:
    2021
  • 资助金额:
    $ 49.07万
  • 项目类别:
Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung Injury
靶向 TLR 信号通路以减弱病原体介导的急性肺损伤
  • 批准号:
    9306674
  • 财政年份:
    2017
  • 资助金额:
    $ 49.07万
  • 项目类别:
Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung Injury
靶向 TLR 信号通路以减弱病原体介导的急性肺损伤
  • 批准号:
    10098763
  • 财政年份:
    2017
  • 资助金额:
    $ 49.07万
  • 项目类别:
Development of VLP vaccine for RSV
RSV VLP 疫苗的开发
  • 批准号:
    9897525
  • 财政年份:
    2014
  • 资助金额:
    $ 49.07万
  • 项目类别:
Development of VLP vaccine for RSV
RSV VLP 疫苗的开发
  • 批准号:
    9137089
  • 财政年份:
    2014
  • 资助金额:
    $ 49.07万
  • 项目类别:
Development of VPL Vaccine for RSV
RSV VPL 疫苗的开发
  • 批准号:
    8645890
  • 财政年份:
    2014
  • 资助金额:
    $ 49.07万
  • 项目类别:
Development of VLP vaccine for RSV
RSV VLP 疫苗的开发
  • 批准号:
    9334692
  • 财政年份:
    2014
  • 资助金额:
    $ 49.07万
  • 项目类别:
Eritoran (E5564), a TLR4 antagonist, as a novel therapeutic for influenza
Eritoran (E5564),一种 TLR4 拮抗剂,作为流感的新型治疗剂
  • 批准号:
    8884533
  • 财政年份:
    2013
  • 资助金额:
    $ 49.07万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 49.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 49.07万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 49.07万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 49.07万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 49.07万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 49.07万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 49.07万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 49.07万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 49.07万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 49.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了